TLPH

Peers: CPIX AMPH RMTI CRMD HRTX PCRX OM BAX NEPH ICUI

Index	-
Market Cap	55.21M
Enterprise Value	44.63M
Income	-15.08M
Sales	0.00M
Book/sh	0.28
Cash/sh	0.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Feb 11, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.83
P/C	3.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.29
Current Ratio	4.29
Debt/Eq	0.45
LT Debt/Eq	0.45
Option/Short	Yes / Yes

EPS (ttm)	-0.26
EPS next Y	-0.21
EPS next Q	-0.05
EPS this Y	41.18%
EPS next Y	-5.00%
EPS next 5Y	28.04%
EPS past 3/5Y	- 48.69%
Sales past 3/5Y	- -65.11%
EPS Y/Y TTM	35.57%
Sales Y/Y TTM	-96.30%
EPS Q/Q	43.47%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	4.00% -

Insider Own	25.69%
Insider Trans	0.00%
Inst Own	46.23%
Inst Trans	0.55%
ROA	-69.60%
ROE	-143.36%
ROIC	-72.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.78%
SMA50	-6.92%
SMA200	5.15%
Trades

Shs Outstand	51.91M
Shs Float	38.57M
Short Float	2.76%
Short Ratio	6.09
Short Interest	1.07M
52W High	1.57 -32.24%
52W Low	0.69 54.94%
Volatility	3.38% 4.09%
ATR (14)	0.04
RSI (14)	43.19
Beta	0.77
Rel Volume	0.02
Avg Volume	174.85K
Volume	196

Perf Week	-0.58%
Perf Month	-5.86%
Perf Quarter	-21.78%
Perf Half Y	19.46%
Perf YTD	-6.68%
Perf Year	-20.61%
Perf 3Y	104.77%
Perf 5Y	-94.12%
Perf 10Y	-98.03%
Recom	1.00
Target Price	3.12
Prev Close	1.03
Price	1.06
Change %	3.28%

Consensus

Strong Buy

Avg. Price Target

$3.12

Implied Upside

+193.3%

Analysts9incl. previous ratings

Rating Distribution5 Buy · 3 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 05, 2026	Resumed	HH.C. Wainwright	Buy	$3	+182.0%
Jan 28, 2025	Initiated	RRodman & Renshaw	Buy	$4	+276.0%
Jul 20, 2020	Downgrade	CCredit Suisse	Neutral → Underperform
Nov 11, 2019	Downgrade	CCredit Suisse	Outperform → Neutral	$7 → $2	+88.0%
Aug 05, 2019	Resumed	CCredit Suisse	Outperform
Jul 10, 2019	Resumed	CCredit Suisse	Outperform
Apr 24, 2019	Resumed	BB. Riley FBR	Buy	$6.50	+511.0%
Feb 15, 2019	Initiated	CCredit Suisse	Outperform	$7	+558.0%
Oct 23, 2018	Initiated	BB. Riley FBR	Buy	$9	+746.0%
Oct 13, 2017	Reiterated	RRBC Capital Mkts	Outperform	$6 → $5	+370.0%
Oct 13, 2017	Downgrade	JJefferies	Buy → Hold
Jul 14, 2017	Resumed	JJefferies	Buy	$7	+558.0%
Sep 15, 2016	Reiterated	RROTH Capital	Buy	$11.25 → $15	+1,310.0%
Aug 05, 2016	Downgrade	SStifel	Buy → Hold
Oct 30, 2015	Upgrade	JJefferies	Hold → Buy
Oct 05, 2015	Reiterated	RROTH Capital	Buy	$8.50 → $10.50	+887.0%
Sep 02, 2015	Initiated	HH.C. Wainwright	Buy	$8.50	+699.0%
Jul 10, 2015	Resumed	RROTH Capital	Buy	$7.50	+605.0%
May 06, 2015	Reiterated	MMizuho	Neutral	$5.50 → $3	+182.0%
May 05, 2015	Reiterated	RRBC Capital Mkts	Outperform	$8 → $7	+558.0%

Sep-03-26 08:30AM	Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-13-26 01:03AM	Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ... (GuruFocus.com) -13.57%
Aug-12-26 04:11PM	Talphera: Q2 Earnings Snapshot (Associated Press)
04:05PM	Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
Aug-05-26 04:05PM	Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026 (PR Newswire) +5.93%
01:02AM	Loading…
May-14-26 01:02AM	Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ... (GuruFocus.com)
May-13-26 04:15PM	Talphera: Q1 Earnings Snapshot (Associated Press) +5.11%
04:05PM	Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
May-07-26 04:05PM	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026 (PR Newswire)
Mar-25-26 08:30AM	Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 (PR Newswire) +9.08%
Mar-23-26 08:44AM	Talphera: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (PR Newswire)
Mar-18-26 04:05PM	Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 (PR Newswire) -8.20%
Mar-02-26 08:30AM	Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial (PR Newswire)
Nov-13-25 12:00AM	Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ... (GuruFocus.com) -18.60%
04:23PM	Loading…
Nov-12-25 04:23PM	Talphera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-25 04:05PM	Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025 (PR Newswire) -8.66%
Oct-21-25 08:30AM	Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
Sep-08-25 08:30AM	Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire) +49.13%
Aug-26-25 08:35AM	Talphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trial (TipRanks)
Aug-25-25 08:30AM	Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial (PR Newswire) +16.62%
Aug-19-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-15-25 03:24AM	Talphera Inc (TLPH) Q2 2025 Earnings Call Highlights: Strategic Adjustments and Enrollment ... (GuruFocus.com)
Aug-14-25 04:15PM	Talphera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-25 04:35PM	Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025 (PR Newswire)
May-15-25 03:16AM	Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... (GuruFocus.com)
May-14-25 04:05PM	Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
May-07-25 04:05PM	Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 (PR Newswire) +6.97%
12:00PM	Loading…
May-06-25 12:00PM	All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy (Zacks)
Apr-04-25 12:00PM	Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.35%
Apr-01-25 03:03AM	Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights (GuruFocus.com) +7.07%
Mar-31-25 06:33PM	Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript (Seeking Alpha) -15.53%
04:05PM	Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million (PR Newswire)
Mar-26-25 04:38PM	Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 (PR Newswire)
Jan-14-25 08:30AM	Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study (PR Newswire)
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-14-24 02:14AM	Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com) -25.61%
Nov-13-24 04:05PM	Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-24 04:05PM	Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 (PR Newswire)
Oct-08-24 04:54PM	Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Sep-05-24 04:15PM	Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +5.62%
Aug-19-24 08:30AM	Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit (PR Newswire)
Aug-14-24 04:01PM	Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) -5.49%
Aug-05-24 04:05PM	Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 (PR Newswire)
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +6.02%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +5.88%
May-20-24 05:25PM	Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-16-24 05:45PM	Talphera to Participate at A.G.P. Virtual Healthcare Conference (PR Newswire) -5.35% -6.09%
May-14-24 08:56PM	TLPH Stock Earnings: Talphera Beats EPS for Q1 2024 (InvestorPlace) +19.12%
04:05PM	Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-02-24 04:15PM	Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 (PR Newswire)
Mar-06-24 09:53PM	TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.63%
04:05PM	Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Mar-01-24 07:30AM	Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members (PR Newswire)
Feb-26-24 04:15PM	Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 (PR Newswire)
Jan-18-24 08:30AM	Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering (PR Newswire) +26.01%
Jan-09-24 09:05AM	AcelRx Announces Rebranding With Name Change to Talphera, Inc. (PR Newswire) +7.50%
Dec-12-23 08:30AM	AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States (PR Newswire) -9.01%
Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks) +10.88%
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.00%
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Mar 13 '26	Buy	0.59	213,310	125,000	800,705	Mar 25 07:57 PM
Angotti Vincent J.	CHIEF EXECUTIVE OFFICER	Feb 12 '26	Buy	0.81	105,364	85,587	586,954	Feb 20 08:28 PM
Aslam Shakil	Chief Medical Officer	Feb 12 '26	Buy	0.81	35,000	28,430	83,178	Feb 20 08:27 PM
Dasu Badri N	Chief Engineering Officer	Feb 12 '26	Buy	0.81	35,000	28,430	76,230	Feb 20 08:25 PM
ASADORIAN RAFFI	Chief Financial Officer	Feb 12 '26	Buy	0.81	45,000	36,554	91,256	Feb 20 08:23 PM

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes Nafamostat, LTX-608, and Niyad. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

CEO & DirectorMr. Vincent J. Angotti

Chief Financial OfficerMr. Raffi Mark Asadorian

Chief Medical OfficerDr. Shakil Aslam M.D.

Chief Engineering OfficerMr. Anil N. Dasu

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Talphera Inc

Upgrade your Finviz experience